Study of the gut microbiome in Egyptian patients with Parkinson’s Disease

Background Recently, an important relationship between Parkinson’s disease and the gut microbiota, through the brain-gut axis interactions, has been established.

Previous studies have declared that alterations in the gut microbiota have a great impact on the pathogenesis and clinical picture of Parkinson’s disease (PD).

The present study aimed to identify the gut microbiome that is likely related to Parkinson’s disease as well as their possible relation to clinical phenotypes.

Methods Thirty patients with Parkinson’s disease, who presented to the Parkinson’s disease Neurology Clinic of Alexandria University Hospital were enrolled in our study.

A cross-matching control group of 35 healthy subjects of similar age and sex were included.

Stool specimens were taken from each.

Quantitative SYBR Green Real-Time PCR was done for the identification and quantitation of selected bacterial phyla, genera and/or species.

Results There was a significant increase in Bacteroides and a significant decrease of Firmicutes and Firmicutes / Bacteroidetes ratio and Bifidobacteria in PD patients.

Although Prevotella was decreased among PD patients relative to the healthy control, the difference was not statistically significant.

Comparing the PD clinical phenotypes with the control group, the Mixed phenotype had significantly higher Bacteroides , Tremors predominant had lower Firmicutes and Firmicutes / Bacteroidetes ratio, and both tremors and postural instability and gait disability (PIGD) phenotypes had lower Bifidobacteria .

However, there was no statistically significant difference between these phenotypes.

Furthermore, when comparing tremors and non-tremors predominant phenotypes; Lactobacilli showed a significant decrease in non-tremors predominant phenotypes.

Conclusions The current study showed evidence of changes in the gut microbiome of Parkinson’s disease patients compared to the healthy controls.

These observations may highlight the importance of the identification of microbiome and specific bacterial changes that can be targeted for the treatment of Parkinson’s disease.